Sabrina Paganoni, Brittney Harkey, Elisa Giacomelli, Merit Cudkowicz, on behalf of the HEALEY ALS Platform Trial Study Group
{"title":"肌萎缩性脊髓侧索硬化症 HEALEY 适应性平台试验的启示。","authors":"Sabrina Paganoni, Brittney Harkey, Elisa Giacomelli, Merit Cudkowicz, on behalf of the HEALEY ALS Platform Trial Study Group","doi":"10.1038/s43587-024-00740-x","DOIUrl":null,"url":null,"abstract":"Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.","PeriodicalId":94150,"journal":{"name":"Nature aging","volume":"4 11","pages":"1512-1515"},"PeriodicalIF":17.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis\",\"authors\":\"Sabrina Paganoni, Brittney Harkey, Elisa Giacomelli, Merit Cudkowicz, on behalf of the HEALEY ALS Platform Trial Study Group\",\"doi\":\"10.1038/s43587-024-00740-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.\",\"PeriodicalId\":94150,\"journal\":{\"name\":\"Nature aging\",\"volume\":\"4 11\",\"pages\":\"1512-1515\"},\"PeriodicalIF\":17.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature aging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s43587-024-00740-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature aging","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s43587-024-00740-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis
Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.